Items tagged with Access
Time for $5 Coalition statement: Cepheid’s updated GeneXpert pricing does not address country needs (post with simple image)
The Time for $5 Coalition calls out Cepheid for not including price reductions of Xpert tests in their updated GeneXpert pricing packages for low- and middle-income countries.
Substantial public investments in GeneXpert underscore need for affordable pricing (post with simple image)
PLOS ONE publishes TAG’s comprehensive analysis of public investments in the development of rapid technology for diagnosing infectious diseases.
Advocates ring the alarm on TB medicines and diagnostics stock outs across India (post with simple image)
Civil society networks in India call for the Ministry of Health and Family Welfare and the National TB Elimination Program to take urgent action.
International support for compulsory license to address access barriers to life-saving TB medicines (post with simple image)
Advocates urge the Indian government to issue compulsory licenses for patents on bedaquiline and delamanid to make the drugs more affordable and accessible.
TAGline: Delivering on the promise of long-acting formulations (post with simple image)
October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria.
Advocates urge Cepheid to reinstate plans to commercialize GeneXpert Omni (post with simple image)
Advocates call out Cepheid for canceling commercialization of the portable point-of-care GeneXpert Omni testing instrument and urge the company to reinstate plans to launch Omni, reiterating demands for Cepheid to reduce the price of GeneXpert tests to $5, inclusive of service and maintenance, across diseases.
Page 70 of 70 · Total posts: 0←First 69 70